Joel Greenblatt’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-5,367
Closed -$457K – 1896
2026
Q2
$457K Buy
+5,367
New +$385K ﹤0.01% 1537
2017
Q3
– Sell
-16,860
Closed -$204K – 932
2017
Q2
$204K Sell
16,860
-33,047
-66% -$459K ﹤0.01% 902
2017
Q1
$641K Buy
+49,907
New +$583K 0.01% 730

Other funds holding CYTK

Joel Greenblatt's CYTK Position: Q3 2026 in Review

Joel Greenblatt sold out of Cytokinetics (CYTK) in Q3 2026, closing a stake of 5,367 shares — an estimated $457K sold.

Joel Greenblatt first reported a position in CYTK in Q1 2017 and held it in 3 quarters. The position peaked at $641K in Q1 2017. 466 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • Joel Greenblatt reported no remaining Cytokinetics position as of Q3 2026 after selling out during the quarter.
  • Joel Greenblatt sold 5,367 Cytokinetics shares in Q3 2026, an estimated $457K.
  • Joel Greenblatt first reported a position in Cytokinetics in Q1 2017 and held it in 3 quarters.
  • Joel Greenblatt's Cytokinetics position peaked at $641K in Q1 2017.
  • 466 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.